GlobeNewswire

Notice on Convocation of Extraordinary General Meeting of Shareholders of AB Klaipedos nafta

Share

Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipedos Nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Extraordinary General Meeting of Shareholders of the Company will be held on 12 December 2019 at 1:00 p.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor).

Agenda of the meeting:

  1. Regarding the approval of the additional decision of the Board of AB Klaipėdos nafta to pledge from 2025 all current and future amounts receivable (the Security Component) of the Company for the benefit of the Ministry of Finance of the Republic of Lithuania for the state guarantee granted by the Republic of Lithuania;
  2. Regarding the approval of the additional decision of the Board of AB Klaipėdos nafta to obtain and present up to EUR 20,000,000 (twenty million euros) annual bank guarantee for the benefit of the Ministry of Finance of the Republic of Lithuania for the state guarantee granted by the Republic of Lithuania.

The shareholders will be registered from 12:00 a.m. to 12:55 p.m. The persons intending to participate in the meeting shall have a personal ID document (an authorized representative shall have an authorization approved under the established procedure. The natural person’s authorization shall be notarized. An authorization issued in a foreign state shall be translated into the Lithuanian language and legalized under the procedure prescribed by the laws).

A shareholder or his proxy shall have the right to vote in writing in advance by filling in a general ballot paper. At the request of the shareholder, the Company shall send a general ballot paper to the shareholder by registered mail free of charge at least 10 days before the meeting. The filled-in general ballot paper and the document attesting the voting right shall be submitted to the Company no later than until the meeting, sending by registered mail or providing them at the address of the registered office of the Company indicated in the notice.

The shareholders who hold shares carrying at least 1/20 of all the votes may propose additions to the agenda of the general meeting of shareholders by submitting with every proposed additional item of the agenda a draft resolution of the general meeting of shareholders or, when no resolution is required, an explanation. Proposals on addition to the agenda shall be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: info@kn.lt and i.berzauskas@kn.lt. The agenda shall be supplemented if the proposal is received no later than 14 days before the Ordinary General Meeting of Shareholders. If the agenda of the general meeting of shareholders is supplemented, the Company shall notify on the additions no later than 10 days before the meeting in the same ways as in the case of convocation of the meeting.

The shareholders, who hold shares carrying at least 1/20 of all the votes, at any time before the general meeting of shareholders or during the meeting, may propose new draft resolutions on items which are or will be included in the agenda of the meeting. The proposals may be submitted in writing or sent by e-mail. Written proposals shall be submitted to the Company on business days or sent by registered mail at the address of the registered office of the Company indicated in the notice. Proposals submitted by e-mail shall be sent to the following e-mails: info@kn.lt and i.berzauskas@kn.lt.

The shareholders shall have the right to submit to the Company in advance questions relating to the items on the agenda of the meeting. The shareholders may submit their written questions to the Company on business days or send by registered mail at the address of the registered office of the Company indicated in the notice no later than 3 business days before the meeting. The Company will reply to the questions by e-mail or in writing before the meeting, except the questions which are related to the Company’s commercial (industrial) secret, confidential information or which have been submitted later than 3 business days before the meeting.

The Company does not provide the possibility of participating and voting at the meeting by means of electronic communications.

The shareholder shall have the right to authorize through electronic communications means another person (natural or legal) to participate and vote in the meeting on behalf of the shareholder. No notarization of such authorization is required. The shareholder must confirm the proxy issued through electronic communications means by an electronic signature developed by a secure signature-creation device and approved by a qualified certificate effective in the Republic of Lithuania. The shareholder shall inform the Company on the proxy issued through electronic communications means to the following e-mails: info@kn.lt and i.berzauskas@kn.lt no later than until the last business day before the meeting at 1:00 p.m. The proxy and the notice must be issued in writing. The proxy and the notice to the Company shall be signed with the electronic signature but not the letter sent by e-mail. By submitting the notice to the Company, the shareholder shall include the internet address from which it would be possible to download software free of charge to verify the shareholder’s electronic signature.

The record date of the meeting shall be 5 December 2019 (only those persons who will be shareholders of the Company at the close of the record date of the general meeting of shareholders or their authorized persons, or persons with whom an agreement on assignment of the voting right has been executed, may participate and vote at the general meeting of shareholders).

The shareholders of the Company may familiarise with the draft resolution of the meeting and the form of the general ballot paper under the procedure prescribed by the laws in the registered office of the Company at Buriu str. 19, Klaipeda (tel.: 8 46 391636), or on the Company’s website at http://www.kn.lt/. The following information and documents shall be provided on the abovementioned internet website of the Company:

- The notification on convocation of the meeting;

- Total number of the Company’s shares and the number of shares with voting rights on the convening day of the meeting.

Enclosed:

  1. Draft decisions;
  2. Ballot paper.



         Jonas Lenkšas, Chief Financial Officer, +370 694 80594.

Attachments

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

New Group Chief Financial Officer13.12.2019 15:20:00 CETPress release

COMPANY ANNOUNCEMENT NO. 15-2019, DECEMBER 13, 2019, COPENHAGEN Roland M. Andersen is appointed Chief Financial Officer and member of Group Executive Management. In continuation of company announcement no. 14, we are pleased to announce the appointment of our new Chief Financial Officer and member of Group Executive Management. Roland M. Andersen joins FLSmidth from NKT and brings 25 years of solid experience and new competences through his time as CFO with public as well as private equity owned companies which will help strengthen FLSmidth. Roland is a strong financial executive with demonstrated success from his prior CFO roles at A.P. Moller Maersk, Telenor/Cybercity, Torm and most recently NKT where he played a key role in leading the company through strategic transformation and further acted as CEO for a period of time. Roland also brings international experience to FLSmidth having lived and worked abroad in Asia and other parts of the world. “We are excited that Roland has decide

Nokia signs contract with TIM Brazil to launch IoT offer13.12.2019 14:00:00 CETPress release

Press Release Nokia signs contract with TIM Brazil to launch IoT offer Nokia’s first Worldwide IoT Network Grid (WING) deal in Latin America, enabling TIM to expand IoT services in Brazil TIM’s enterprise customers will be able to offer IoT services across various industries faster by using the fully virtualized WING infrastructure, offered as a managed service Widespread adoption of IoT technologies estimated to add USD 200 billion to Brazilian economy by 2025* 12 December 2019 Espoo, Finland – Nokia has signed a contract with telecommunications giant TIM to provide Internet of Things (IoT) services to its enterprise customers in Brazil. Using the fully virtualized Nokia Worldwide IoT Network Grid (WING) managed service offer, TIM and its enterprise customers across industries,such as automotive and agriculture, will be able to capture IoT opportunities faster and more securely. The Brazilian market is the largest IoT market in Latin America, with widespread adoption of IoT technologi

Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD13.12.2019 13:03:00 CETPress release

In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-retinal fluid and/or sub-retinal fluid at week 16 and year one with Beovu1 In a key pre-specified secondary endpoint, over half of Beovu 6mg patients (56% in HAWK and 51% in HARRIER) were maintained on three-month dosing intervals immediately after the loading phase through year one1 Frequent injections are a common reason patients drop off treatment for wet AMD, a leading cause of blindness that affects more than 20M people worldwide2-4 Basel, December 13, 2019 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu® (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD). “Today’s CHMP opinion brings us ano

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business13.12.2019 13:00:00 CETPress release

OUTOTEC OYJ STOCK EXCHANGE RELEASE December 13, 2019 at 2:00 PM The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business The Finnish Financial Supervisory Authority has today on December 13, 2019, approved a supplement to the Finnish language demerger prospectus (the “Prospectus”) relating to the combination of Outotec Oyj (“Outotec”) and Metso Corporation’s (“Metso”) Minerals business (the “Metso Minerals Business”). The supplement relates to the stock exchange release published by Outotec on December 10, 2019, according to which Outotec has taken a strategic decision to divest three businesses in the Metals, Energy & Water segment, which are the aluminum business, waste-to-energy solutions and sludge incineration. The supplement also relates to the stock exchange release published by Outotec on the same day, according to which Outotec lowers its sales guidance for 2019 due to the in

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business13.12.2019 13:00:00 CETPress release

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business Metso Corporation, Stock exchange release on December 13, 2019, at 2:00 p.m. EET The Finnish Financial Supervisory Authority has today on December 13, 2019, approved a supplement to the Finnish language demerger prospectus (the “Prospectus”) relating to the combination of Outotec Oyj (“Outotec”) and Metso Corporation’s (“Metso”) Minerals business (the “Metso Minerals Business”). The supplement relates to the stock exchange release published by Outotec on December 10, 2019, according to which Outotec has taken a strategic decision to divest three businesses in the Metals, Energy & Water segment, which are the aluminum business, waste-to-energy solutions and sludge incineration. The supplement also relates to the stock exchange release published by Outotec on the same day, according to which Outotec lowers its sales guidance for 2

Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline13.12.2019 10:26:00 CETPress release

COPENHAGEN, Denmark, December 13, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has received antitrust clearance in the U.S., Spain and Portugal of its planned acquisition of the two commercial vaccines, Rabipur®/RabAvert® and Encepur®, from GlaxoSmithKline plc (GSK), announced on October 21, 2019. With these clearances, and the recent approval from the Company’s shareholders of a rights issue to fund part of the acquisition, the transaction will now proceed towards closing, expected by December 31, 2019. For more information about the transaction, see company announcement no. 19/2019. About Bavarian Nordic Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative therapies against infectious diseases and cancer. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to unlock the power of the immune system to improve p